A Safety Run-In/Randomized Phase II Trial Of EMD 121974 In Conjunction With Concomitant Temozolomide and Adjuvant Temozolomide With Radiation Therapy In Patients With Newly Diagnosed Glioblastoma Multiforme.
Phase of Trial: Phase I/II
Latest Information Update: 29 Feb 2016
At a glance
- Drugs Cilengitide (Primary) ; Temozolomide
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Apr 2012 Actual end date changed from May 2011 to March 2012 as reported by ClinicalTrials.gov.
- 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.